Oncology Impact Fund (Cayman) Management L.P., 10% Owner at TCR2 THERAPEUTICS INC. (TCRR), bought 949,207 shares at $15.00 ($10.0M) on 2019-02-19, disclosed to the SEC on 2019-02-21.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.00 | 282,540 | $0 | 0.0% |
| 2 | $15.00 | 666,667 | $10.0M | 100.0% |
| Total | $10.54 avg | 949,207 | $10.0M | 100% |
| Filing → |
| ITOS | SELL | 2021-11-24 | $8.9M | — | Filing → |
| ITOS | SELL | 2021-10-18 | $1.6M | — | Filing → |
| ITOS | SELL | 2021-10-12 | $4.6M | — | Filing → |